Thanks to your activism, the FDA has agreed to study bioidentical hormone replacement therapy. But the threat to hormones still looms. For months now, we’ve been telling you about the FDA’s attack on estriol, progesterone, and other bioidentical hormones that are made for individual patients at specialized pharmacies. Now, thanks to the activism of ANH members and other stakeholders, the agency has recently announced that they have asked the National Academies of Science, Engineering, and Medicine (NASEM) to conduct a study on bioidentical hormone replacement therapy (BHRT). This is a qualified victory: it shows that the FDA feels enough pressure from the public that they can’t ban bioidentical hormones outright. But the fight is far from over, and we must remain vigilant to ensure the future of bioidentical hormone replacement therapy (BHRT).
With their great safety profile and excellent health benefits, it isn’t surprising that one third of women who use hormone therapy choose estriol and other safe, effective, and natural bioidentical hormones to manage the symptoms of menopause. Unfortunately, the FDA is poised to remove access to these hormones and to leave ailing women with no other option but more dangerous alternatives. ANH-USA is leading the charge to protect these crucial hormones, but we need your help to enlist members of Congress to get the FDA to back off.
Many millions of women depend on estriol. In 2008, the FDA – likely acting upon a petition it received from Wyeth Pharmaceuticals, the manufacturer of Premarin (an estrogen drug made from pregnant horse mares’ urine) – went after bioidentical hormones, particularly estriol. Thanks to ANH members and the wider natural health community, the FDA backed off. Now, they see an opportunity to remove estriol and other hormones by other means and we must once again mobilize to stop them.